It is established that delayed effective pharmacotherapy plays a significant role in the overall burden of psychiatric disorders, which are often treated with symptomatic drugs, that is benzodiazepines (BZDs), in relation to their rapid onset of action and safety, despite long-term side effects. We aimed to assess the influence of initial treatment with BZDs on the duration of untreated illness (DUI) and whether specific sociodemographic and clinical factors could influence the choice of BZDs as first treatment in 545 patients affected by schizophrenia, mood and anxiety spectrum disorders. Statistical analyses (one-way analysis of variance and χ 2 ) were carried out to compare patients who used BZDs as first treatment (BZD w/) and those who did not (BZD w/o). The overall DUI, irrespective of diagnosis, resulted in significantly longer in BZD w/ versus w/o patients, who also experienced more frequently anxious/depressive symptoms at onset. Furthermore, BZD w/ patients more frequently autonomously decided to look for treatment (mainly refering to psychologists or general practitioners) and experimented more frequently phobias, than BZD w/o ones. The present findings suggest that initial BZDs treatment may prolong the overall DUI, although their prescription seems to be influenced by specific sociodemographic and clinical factors. Further studies are needed to confirm the present findings. Int Clin Psychopharmacol 33:140-146 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Mental disorders are highly prevalent and disabling conditions, estimated to contribute towards 5.4% of Disability-Adjusted Life Years and 17.4% of global Years Lived with Disability (Charara et al., 2017) . There is a univocal consensus on the burden of mental disorders on patients' quality of life and global functioning and, in many cases, on related caregivers' quality of life (Wagner et al., 2006) . Indeed, psychiatric disorders often remain underdiagnosed and not adequately treated as a consequence of many factors, including also social stigma and lack of knowledge of mental health (Wei et al., 2017) .
All the mentioned factors may contribute towards extending the overall duration of untreated illness (DUI) and towards worsening the prognosis and response to psychopharmacological treatment in specific subgroups of patients.
With respect to DUI, even though different definitions exist in the literature (Breitborde et al., 2009) , it is mainly defined as the time elapsing from the onset of a psychiatric disorder and the subsequent administration of the first pharmacological treatment at standard dosages, for an adequate period of time in a compliant patient, according to treatment guidelines (Dell'Osso and Altamura, 2010) . Several mental illnesses, such as schizophrenia spectrum disorders (McGlashan, 1999; Barnes et al., 2000; Marshall et al., 2005; Perkins et al., 2005; Penttilä et al., 2010; Buoli et al., 2013) , depressive disorders (Dell'Osso and Altamura, 2010), anxiety disorders (Altamura et al., 2005 (Altamura et al., , 2008 Ghio et al., 2014) and obsessive compulsive disorder (OCD) (Dell'Osso et al., 2015a , 2015b , have been investigated in relation to the DUI, underlying its predictive role in treatment outcome and the importance of early intervention to prevent long-term disability (Dell'Osso and Altamura, 2010).
Benzodiazepines (BZDs) represent one of the largest and most widely prescribed classes of psychotropic drugs, particularly at the onset of several psychiatric disorders (Dell'Osso and Lader, 2013) . According to guideline recommendations, anxiety and mood disorders, sleep disorders, alcohol withdrawal, delirium and aggressive behaviour in psychoses seem to represent the clinical conditions of more frequent use for BZDs (Ashok, 2006; Bandelow et al., 2008; Kennedy et al., 2009; .
More in detail, in psychiatric clinical practice, mental disorders, especially at the onset, might be underestimated and often initially treated exclusively with symptomatic drugs, that is, BZDs . In fact, BZDs present a rapid onset of action and a favourable safety profile, but also have considerable short-term and long-term side effects. Indeed, BZDs can induce dose-dependent tolerability problems, such as sedation, fatigue, lethargy, drowsiness, hangover and rebound symptoms after interruption, cognitive impairment, development of dependence, hypotonia and ataxia (Buffett-Jerrott and Stewart, 2002; Lader et al., 2009; Koyama et al., 2013; Pariente et al., 2016) . Moreover, a higher risk of dementia was found among long-term users of BZDs, especially for long-acting compounds (Billioti de Gage et al., 2014; Shash et al., 2016) .
Another understated aspect is BZDs treatment during breastfeeding as postpartum depression represents a prevalent condition and sedating drugs could cause central nervous system depression in infants (Chow and Koren, 2015) .
In relation to BZDs use and specific psychiatric diagnoses, patients with major depressive disorder (MDD) and anxiety disorders were observed to report massive use of BZDs as first treatment compared with patients with schizophrenia spectrum disorders (Dell'Osso et al., 2015a , 2015b .
On the basis of the above-mentioned investigation, the present study primarily aimed to evaluate the influence of treatment with BZDs on the DUI, these compounds providing fast symptom relief that might delay the first prescription of an adequate and clinically approved pharmacological treatment. The secondary aim was to assess whether specific sociodemographic or clinical factors could influence the choice of BZDs as first treatment in patients affected by schizophrenia, mood and anxiety spectrum disorders. We hypothesized that results might help to better characterize specific clinical features in psychiatric disorders to identify patients at higher risk of BZDs misuse and potential lack of treatment.
Patients and methods

Sample
The study sample consisted of 545 consecutive patients (both outpatients and inpatients) attending three major psychiatric services in the North (First et al., 2002) , administered by psychiatrists with specific training. In case of comorbid disorder, the condition assessed in relation to the psychopathological onset and DUI had to be the one causing the most significant discomfort to the patient, the greatest impact on quality of life and representing the main motivation for seeking help.
Assessment
Sociodemographic and clinical variables, collected during the clinical interviews, were as follows: sex, age, age at onset, age at first diagnosis, age at first pharmacological treatment, first pharmacological treatment, family history for psychiatric disorders, occurrence of onset-related stressful events, use of BZDs as first treatment, first therapist referral (psychiatrist, psychologist, neurologist or other clinician), decision to seek help (autonomous or driven by others) and first therapy setting (outpatient or inpatient). In particular, patients underwent a clinical interview guided by the administration of the psychopathological onset and latency to treatment questionnaire (POLT-Q), a recently developed tool aimed to specifically assess factors characterizing access and latency to first pharmacological treatment in patients with psychiatric disorders. The questionnaire includes a preliminary part, collecting patient sociodemographic features, and two sections, respectively, focused on psychopathological onset (section 1) and first pharmacological treatment (section 2). POLT-Q is a brief, clinician-administered questionnaire that was found to be easy to administer by clinicians and well accepted by patients (Dell'Osso et al., 2017). As conventionally accepted (Dell'Osso and Altamura, 2010; , the DUI was defined as the time interval, in months, elapsing between the onset of the disorder and the administration of the first pharmacological treatment, in compliant patients, at an appropriate dosage and for an adequate period of time, in agreement with recently updated International Treatment Guidelines (Bauer et al., 2013; Grunze et al., 2013) .
Statistical analysis
Descriptive analyses were carried out on the total sample. The study sample was then divided into two subgroups according to the use of BZDs as first treatment. One-way analysis of variance for continuous variables and the χ 2 test for dichotomous ones were carried out for comparison between patients who used BZDs as first treatment (BZD w/) and those who did not (BZD w/o). With respect to continuous variables, a post-hoc test (Bonferroni) was performed. The level of significance for all statistical analyses was set at 0.05.
Results
The sociodemographic and clinical variables of the entire sample (n = 545) are summarized in Table 1 . The sample showed a similar sex distribution (52.8% men and 47.2% women) and had a mean age of 48.1 14.3 years. The mean DUI of the total sample was 59.7 100.3 months.
The comparison between the two subgroups showed different statistically significant results as reported in Table 2 .
In particular, the DUI was significantly longer in BZD w/ versus w/o patients (72.9 105.9 vs. 53.1 96.9 months; P < 0.05), as shown in Fig. 1 . Moreover, BZD w/ patients reported anxious/depressive symptoms more frequently at onset (31 vs. 21%, P < 0.01), and psychotic symptoms less frequently (12 vs. 62%, P < 0.01) compared with BZD w/o patients.
BZD w/ patients more often had MDD and adjustment disorders (43 vs. 32% and 9 vs. 3%, respectively), whereas BZD w/o patients had bipolar disorder, OCD and schizophrenia spectrum disorders (18 vs. 10%, 9 vs. 3%, and 11 vs. 4%, respectively; P < 0.0001).
Furthermore, BZD w/ patients more frequently reported an autonomous help-seeking decision (48 vs. 36%, P < 0.01), whereas among BZD w/o patients, their first visit was encouraged by relatives or friends (62 vs. 47%, P < 0.01). BZD w/ patients were found to contact psychologists or general practitioners (GPs) more frequently rather than psychiatrists as first therapists compared with BZD w/o patients (21 vs. 9%, 47 vs. 27%, and 24 vs. 55%, respectively; P < 0.0001).
Finally, BZD w/ patients experienced lifetime comorbid phobia more frequently than BZD w/o patients (24 vs. 16%, P < 0.05).
The remaining sociodemographic and clinical features investigated did not show any significant difference between the two subgroups.
Discussion
In the present study, we sought to assess whether patients with various psychiatric disorders had different latency to BZDs compared with approved treatments for their conditions. BZDs, in fact, represent symptomatic drugs (Verster and Volkerts, 2004) , often useful for fast relief of symptoms, but with the potential limitation of BZ, benzodiazepine; DUI, duration of untreated illness; GAD, generalized anxiety disorder; GP, general practitioners; MDD, major depressive disorder; OCD, obsessive compulsive disorder; PD, panic disorder. Bold font indicates statistically significant results after post-hoc test (Bonferroni). *P < 0.05. **P < 0.01. ****P < 0.0001.
prolonging the overall first psychiatric referral and the administration of the first adequate psychopharmacological treatment. From this perspective, our results showed that BZD w/ patients were found to experience a significantly longer DUI than BZD w/o patients. Moreover, the statistical analysis showed a significant association between BZD w/ patients and the presence of anxious/depressive symptoms at the onset of the illness compared with psychotic manifestations. Previous studies from our group reported that patients with anxiety disorders, particularly GAD, more frequently received BZDs as first therapy . Interestingly, Martin et al. (2007) , in a previous metaanalysis, did not find univocal evidence on the short-term efficacy of BZDs in the menagement of GAD symptoms; a different study reported an improvement in anxiety ratings only during the first weeks of treatment with BZDs, but suggested the prevalent long-term role of antidepressants in patients affected by GAD (Rickels et al., 1993) . Furthermore, in antidepressant treatment-resistant cases of panic disorder, Bandelow et al. (2008) pointed out how BZDs could be useful when the patients do not have a history of substance abuse disorders. Focusing on social anxiety disorder, BZDs showed superior effects than placebo for several symptoms, such as phobic avoidance, interpersonal sensitivity, fears of negative evaluation and disability measures (Davidson et al., 1993) . Moreover, a Cochrane meta-analysis underlined how the association of BZDs to antidepressants might be useful in the short term for patients with MDD, providing symptomatic relief (Furukawa et al., 2001) .
The relevant correlation between BZD w/ patients and the presence of anxious/depressive symptoms at onset of illness, found in our study, may be explained in light of the tendency of anxious disorders to manifest in an insidious way (Roy-Byrne and Wagner, 2004) . However, patients with psychotic spectrum disorders, which usually have an acute onset (American Psychiatric Association, 2013), reported a first psychiatric referral more frequently because of a more severe clinical presentation and more frequent hospital admission at the onset (Dell'Osso et al., 2015a , 2015b .
Another relevant result of the present study is that BZD w/ patients were found to contact psychologists or GPs, rather than psychiatrists, more frequently as first therapists compared with BZD w/o patients. Previous studies reported that patients with an anxiety disorder often contact their GP rather than a psychiatrist (Dell'Osso et al., 2015a , 2015b and BZDs are frequently prescribed by GPs as initial treatments for anxiety (Baldwin et al., 2012; Dell'osso and Lader, 2013) , even though treatment guidelines recommend the use of second-generation antidepressants (Baldwin et al., 2014; Starcevic, 2014) .
Many recent studies focused on BZDs prescription patterns, underlying, in particular, how these compounds are widely administered and frequently misused, and suggesting the importance of reducing inappropriate BZDs use, improving evidence-based practice and prescription monitoring across different countries. More in detail, a Norwegian study of primary care reviewed 3452 prescriptions for BZDs prescribed by GPs over 2 months (Straand and Rokstad, 1997) . Of these, over half were prescribed to patients older than 65 years of age, showing that BZDs are prescribed extensively by GPs in patients affected by different psychiatric conditions, especially mood and anxiety disorders, also including the elderly population. The broad BZDs prescription has been shown not only in the Norwegian population (Fride Tvete et al., 2015) , but elsewhere as well. For instance, BZDs harmful misuse has been pointed out by different studies in Canada (Murphy et al., 2016) , the USA (Bachhuber et al., 2016) , France (Rosman et al., 2011) and the UK (Davies et al., 2017) . All these studies focused on the need to recognize BZDs misuse as a major public health problem and highlighted the need for a specific intervention to reduce BZDs inappropriate prescriptions.
From this perspective, it is crucial not only to educate the population about BZDs misuse but also to involve the GPs, for more appropriate prescription of these compounds, considering their side effects (Albrecht et al., 2014) and the risk of delaying the initiation of a more appropriate pharmacological treatment, as pointed out by the results of the present study. Indeed, although BZDs can initially be useful in relieving acute psychiatric symptoms, they carry the risk of dependence and withdrawal (Bandelow et al., 2008) . In addition, their longterm use has been associated with impaired cognitive attention (Petursson et al., 1983) and verbal memory (Barker et al., 2004) , a potentially higher risk of dementia (Billioti de Gage et al., 2014) and a major risk of car accidents (Smink et al., 2010) , hip fractures and falls, particularly in the elderly (Bartlett et al., 2009) . Comparison of duration of untreated illness (DUI) between the two subgroups (BZD w/ and BZD w/o) and in the total sample. BZD w/, patients who used benzodiazepines as first treatment; BZD w/o, patients who did not use benzodiazepines.
The tendency to contact a GP rather than a psychiatrist for the assessment of psychiatric symptoms and to be treated with symptomatic compounds as initial treatment might be influenced by the stigma towards psychiatric disorders and psychotropic drugs, because of which patients hesitate to choose psychiatrists as first therapists. Del Vecchio and colleagues showed that, among health professionals, GPs were the professionals chosen most frequently by patients with a first episode of psychosis, mainly because of the stigma and the wrong attribution of psychiatric symptoms. These reasons were also linked to delays in seeking help (Del Vecchio et al., 2015) . Moreover, even when relatives recognize the need for psychiatric help for the patient, they prefer to avoid psychiatric referral (Franz et al., 2010; Gerlinger et al., 2013; Windell and Norman, 2013; Griffiths et al., 2014) and more often address to GPs or other 'less stigmatizing' health professionals (Falloon, 2000; Skeate et al., 2002; Tait et al., 2005) . According to the literature, stigma affects not only psychotic disorders, but all mental illnesses, including depressive and anxiety disorders (Jorm and Reavley, 2013) , and has a profound impact on DUI and psychiatric referral. Furthermore, the high levels of stigma towards psychiatric disorders (Magliano et al., 2003; Fiorillo et al., 2011) and the limited availability of specific services for early intervention in many countries (Pollice et al., 2012; Cocchi et al., 2013; Pingani et al., 2014) may represent an important barrier to the psychiatric care of patients in the early phases of the disorder.
Focusing on these considerations, it should be useful to work in two different but complementary directions. First of all, mental health literacy needs to be improved (Jorm, 2000) . Psychiatric patients often do not receive appropriate treatment for many years and must be trained to recognize prodromic symptoms, which should be evaluated by a psychiatrist, and to avoid misuse of symptomatic compounds. Second, GPs could play a key role in limiting BZDs misuse, abuse or dependence, as shown in a recent report highlighting the active involvement of GPs, particularly for educating their patients to cease or reduce BZDs use to decrease BZDs consumption (Darker et al., 2015) .
Even though our sample was quite representative, the following methodological limitations should be pointed out to interpret the aforementioned findings. As the POLT-Q retrospectively collected sociodemographic and clinical variables, the presence of recall bias cannot be excluded, particularly for patients with most remote psychopathological onset and for elderly individuals. Nonetheless, as already mentioned, all clinical data from the POLT-Q were cross-checked with family members/ caregivers and previous medical charts, when available. Moreover, the recruitment of patients from different catchment areas may have reflected local differences in terms of efficiency of psychiatric services as well as different sociocultural attitudes, which, in turn, may have influenced the reported results. In contrast, we only included Italian patients. This inclusion criterion may have produced different results (i.e. because of the number of available psychiatrists and burden because of the stigma linked to psychiatric disorders), for other geographic areas, and it may ultimately represent a methodological limitation.
Conclusion
Specific diagnostic and clinical factors, such as onset symptoms, first diagnosis, personal decision to contact the first therapist, comorbid phobia and first referral, seem to condition BZDs use as first treatment at the onset of different psychiatric disorders. In clinical practice, early detection is important to reduce the DUI, which reflects the latency to approved and evidencebased treatments and could be delayed by inappropriate BZDs use. Further studies are needed to raise awareness of BZDs misuse and better identify patients who require nonsymptomatic treatment. Increasing health literacy and psychiatric disease awareness might be useful to enable GPs, clinicians, patients and the general population to recognize prodromal symptoms and consequently provide the most appropriate pathways of care when necessary.
